Director at Assembly Biosciences (ASMB) receives grant of 8,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Houghton holds 8,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Houghton Michael
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 8,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 8,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 8,000 options
Exercise price: $24.11 per share
Expiration date: June 4, 2036
+2 more
5 metrics
Stock options granted
8,000 options
Grant to director Michael Houghton
Exercise price
$24.11 per share
Stock option strike price
Expiration date
June 4, 2036
Option term end
Underlying shares
8,000 shares
Common stock underlying options
Holdings after grant
8,000 options
Total derivative holdings following transaction
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, annual meeting of stockholders
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
annual meeting of stockholders financial
"the date of the Issuer's 2027 annual meeting of stockholders"
FAQ
What insider transaction did Assembly Biosciences (ASMB) report for Michael Houghton?
Assembly Biosciences reported that director Michael Houghton received a grant of 8,000 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as part of his equity-based compensation from the company.
How many stock options did Michael Houghton receive from Assembly Biosciences (ASMB)?
Michael Houghton received 8,000 stock options. Each option relates to one share of Assembly Biosciences common stock, giving him potential future ownership if he chooses to exercise the options at or above the specified exercise price.
What is the exercise price of Michael Houghton’s Assembly Biosciences (ASMB) stock options?
The exercise price of Michael Houghton’s stock options is $24.11 per share. This means he can buy Assembly Biosciences common stock at $24.11, regardless of the future market price, once the options have vested and before they expire.
When do Michael Houghton’s Assembly Biosciences (ASMB) stock options vest?
The options vest upon the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Vesting is conditioned on Houghton’s continuous service with Assembly Biosciences through that date, aligning his compensation with ongoing board involvement.
When do Michael Houghton’s Assembly Biosciences (ASMB) stock options expire?
Michael Houghton’s stock options expire on June 4, 2036. After this expiration date, any unexercised options become worthless, so he must exercise vested options before that time to acquire shares at the $24.11 exercise price.
How many Assembly Biosciences (ASMB) options does Michael Houghton hold after this grant?
Following this grant, Michael Houghton holds 8,000 stock options directly. The filing does not show additional derivative holdings, so this grant represents his reported option position in Assembly Biosciences common stock as of the transaction date.